BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zegers CM, Hoebers FJ, van Elmpt W, Bons JA, Öllers MC, Troost EG, Eekers D, Balmaekers L, Arts-Pechtold M, Mottaghy FM, Lambin P. Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer. Eur J Nucl Med Mol Imaging 2016;43:2139-46. [PMID: 27251643 DOI: 10.1007/s00259-016-3429-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Köthe A, Lomax AJ, Giovannelli AC, Safai S, Bizzocchi N, Roelofs E, Even AJG, Weber DC, Fattori G. The impact of organ motion and the appliance of mitigation strategies on the effectiveness of hypoxia-guided proton therapy for non-small cell lung cancer. Radiother Oncol 2022;176:208-14. [PMID: 36228759 DOI: 10.1016/j.radonc.2022.09.021] [Reference Citation Analysis]
2 Lin M, Coll RP, Cohen AS, Georgiou DK, Manning HC. PET Oncological Radiopharmaceuticals: Current Status and Perspectives. Molecules 2022;27:6790. [DOI: 10.3390/molecules27206790] [Reference Citation Analysis]
3 Hildingsson S, Gebre-Medhin M, Zschaeck S, Adrian G. Hypoxia in relationship to tumor volume using hypoxia PET-imaging in head & neck cancer - A scoping review. Clin Transl Radiat Oncol 2022;36:40-6. [PMID: 35769424 DOI: 10.1016/j.ctro.2022.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Gallez B. The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia. Front Pharmacol 2022;13:853568. [DOI: 10.3389/fphar.2022.853568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Welz S, Paulsen F, Pfannenberg C, Reimold M, Reischl G, Nikolaou K, La Fougère C, Alber M, Belka C, Zips D, Thorwarth D. Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [18F]FMISO PET/CT. Radiother Oncol 2022:S0167-8140(22)00170-0. [PMID: 35395276 DOI: 10.1016/j.radonc.2022.03.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Rühle A, Grosu A, Wiedenmann N, Ruf J, Bieber B, Stoian R, Thomsen AR, Gkika E, Vaupel P, Baltas D, Weber WA, Mix M, Nicolay NH. The value of plasma hypoxia markers for predicting imaging-based hypoxia in patients with head-and-neck cancers undergoing definitive chemoradiation. Clinical and Translational Radiation Oncology 2022. [DOI: 10.1016/j.ctro.2022.02.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Lapa C, Herrmann K, Troost EGC. Specific PET Tracers for Solid Tumors and for Definition of the Biological Target Volume. Image-Guided High-Precision Radiotherapy 2022. [DOI: 10.1007/978-3-031-08601-4_2] [Reference Citation Analysis]
8 Rühle A, Wiedenmann N, Fennell JT, Mix M, Ruf J, Stoian R, Thomsen AR, Vaupel P, Baltas D, Grosu AL, Nicolay NH. Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation-results from a prospective pilot trial. Eur J Nucl Med Mol Imaging 2021. [PMID: 34773163 DOI: 10.1007/s00259-021-05602-x] [Reference Citation Analysis]
9 Schaner PE, Williams BB, Chen EY, Pettus JR, Schreiber WA, Kmiec MM, Jarvis LA, Pastel DA, Zuurbier RA, DiFlorio-Alexander RM, Paydarfar JA, Gosselin BJ, Barth RJ, Rosenkranz KM, Petryakov SV, Hou H, Tse D, Pletnev A, Flood AB, Wood VA, Hebert KA, Mosher RE, Demidenko E, Swartz HM, Kuppusamy P. First-In-Human Study in Cancer Patients Establishing the Feasibility of Oxygen Measurements in Tumors Using Electron Paramagnetic Resonance With the OxyChip. Front Oncol 2021;11:743256. [PMID: 34660306 DOI: 10.3389/fonc.2021.743256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Huang Y, Fan J, Li Y, Fu S, Chen Y, Wu J. Imaging of Tumor Hypoxia With Radionuclide-Labeled Tracers for PET. Front Oncol 2021;11:731503. [PMID: 34557414 DOI: 10.3389/fonc.2021.731503] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
11 Florea A, Mottaghy FM, Bauwens M. Molecular Imaging of Angiogenesis in Oncology: Current Preclinical and Clinical Status. Int J Mol Sci 2021;22:5544. [PMID: 34073992 DOI: 10.3390/ijms22115544] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
12 Khan R, Seltzer M. PET Imaging of Tumor Hypoxia in Head and Neck Cancer: A Primer for Neuroradiologists. Neuroimaging Clin N Am 2020;30:325-39. [PMID: 32600634 DOI: 10.1016/j.nic.2020.05.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Maleš J, Mihalj H, Šestak A, Kralik K, Smolić M. Osteopontin Levels in Patients with Squamous Metastatic Head and Neck Cancer. Medicina (Kaunas) 2021;57:185. [PMID: 33670031 DOI: 10.3390/medicina57020185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Marcus C, Subramaniam RM. Role of Non-FDG-PET/CT in Head and Neck Cancer. Semin Nucl Med 2021;51:68-78. [PMID: 33246541 DOI: 10.1053/j.semnuclmed.2020.07.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
15 Conen P, Mottaghy FM. Is 68Ga-DOTA-FAPI a new arrow in the quiver of dose painting in radiation dose planning in head and neck cancers? Eur J Nucl Med Mol Imaging 2020;47:2718-20. [PMID: 32488339 DOI: 10.1007/s00259-020-04895-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Joseph N, Kirkby NF, Hoskin PJ, West CML, Choudhury A, Dale RG. Radiobiologically derived biphasic fractionation schemes to overcome the effects of tumour hypoxia. Br J Radiol 2020;93:20190250. [PMID: 32462907 DOI: 10.1259/bjr.20190250] [Reference Citation Analysis]
17 Sanduleanu S, Wiel AMAV, Lieverse RIY, Marcus D, Ibrahim A, Primakov S, Wu G, Theys J, Yaromina A, Dubois LJ, Lambin P. Hypoxia PET Imaging with [18F]-HX4-A Promising Next-Generation Tracer. Cancers (Basel) 2020;12:E1322. [PMID: 32455922 DOI: 10.3390/cancers12051322] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
18 Sanduleanu S, Hamming-Vrieze O, Wesseling FWR, Even AJG, Hoebers FJ, Hoeben A, Vogel WV, Tesselaar MET, Parvin D, Bartelink H, Lambin P. [18F]-HX4 PET/CT hypoxia in patients with squamous cell carcinoma of the head and neck treated with chemoradiotherapy: Prognostic results from two prospective trials. Clin Transl Radiat Oncol 2020;23:9-15. [PMID: 32368624 DOI: 10.1016/j.ctro.2020.04.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
19 Hohenstein NA, Chan JW, Wu SY, Tahir P, Yom SS. Diagnosis, Staging, Radiation Treatment Response Assessment, and Outcome Prognostication of Head and Neck Cancers Using PET Imaging. PET Clinics 2020;15:65-75. [DOI: 10.1016/j.cpet.2019.08.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
20 Hu M, Zhu Y, Mu D, Fan B, Zhao S, Yang G, Ma L, Zheng J, Yu J. Correlation of hypoxia as measured by fluorine-18 fluoroerythronitroimidazole (18F-FETNIM) PET/CT and overall survival in glioma patients. Eur J Nucl Med Mol Imaging 2020;47:1427-34. [PMID: 31776634 DOI: 10.1007/s00259-019-04621-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
21 Huang W, Wang K, An Y, Meng H, Gao Y, Xiong Z, Yan H, Wang Q, Cai X, Yang X, Zhang B, Chen Q, Yang X, Tian J, Zhang S. In vivo three-dimensional evaluation of tumour hypoxia in nasopharyngeal carcinomas using FMT-CT and MSOT. Eur J Nucl Med Mol Imaging 2020;47:1027-38. [PMID: 31705175 DOI: 10.1007/s00259-019-04526-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
22 Yu W, Qiao F, Su X, Zhang D, Wang H, Jiang J, Xu H. 18F-HX4/18F-FMISO-based micro PET for imaging of tumor hypoxia and radiotherapy-associated changes in mice. Biomedicine & Pharmacotherapy 2019;119:109454. [DOI: 10.1016/j.biopha.2019.109454] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
23 Hu M, Xie P, Lee NY, Li M, Ho F, Lian M, Zhao S, Yang G, Fu Z, Zheng J, Ma L, Yu J. Hypoxia with 18F-fluoroerythronitroimidazole integrated positron emission tomography and computed tomography (18F-FETNIM PET/CT) in locoregionally advanced head and neck cancer: Hypoxia changes during chemoradiotherapy and impact on clinical outcome. Medicine (Baltimore) 2019;98:e17067. [PMID: 31577699 DOI: 10.1097/MD.0000000000017067] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
24 Fonti R, Conson M, Del Vecchio S. PET/CT in radiation oncology. Semin Oncol 2019;46:202-9. [PMID: 31378377 DOI: 10.1053/j.seminoncol.2019.07.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
25 Thorwarth D, Welz S, Mönnich D, Pfannenberg C, Nikolaou K, Reimold M, La Fougère C, Reischl G, Mauz PS, Paulsen F, Alber M, Belka C, Zips D. Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic 18F-FMISO PET for Head and Neck Cancer Radiotherapy. J Nucl Med 2019;60:1698-704. [PMID: 31076504 DOI: 10.2967/jnumed.119.227744] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
26 Yang X, Wang F, Zhu H, Yang Z, Chu T. Synthesis and Bioevaluation of Novel [ 18 F]FDG-Conjugated 2-Nitroimidazole Derivatives for Tumor Hypoxia Imaging. Mol Pharmaceutics 2019;16:2118-28. [DOI: 10.1021/acs.molpharmaceut.9b00075] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
27 Betts HM, O'Connor RA, Christian JA, Vinayakamoorthy V, Foweraker K, Pascoe AC, Perkins AC. Hypoxia imaging with [18F]HX4 PET in squamous cell head and neck cancers: a pilot study for integration into treatment planning. Nucl Med Commun 2019;40:73-8. [PMID: 30371605 DOI: 10.1097/MNM.0000000000000933] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
28 Hamming-vrieze O, Navran A, Al-mamgani A, Vogel WV. Biological PET-guided adaptive radiotherapy for dose escalation in head and neck cancer: a systematic review. Q J Nucl Med Mol Imaging 2018;62. [DOI: 10.23736/s1824-4785.18.03087-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
29 Zhu L, Wang L, Liu Y, Xu D, Fang K, Guo Y. CAIX aptamer-functionalized targeted nanobubbles for ultrasound molecular imaging of various tumors. Int J Nanomedicine 2018;13:6481-95. [PMID: 30410333 DOI: 10.2147/IJN.S176287] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
30 Bandurska-Luque A, Löck S, Haase R, Richter C, Zöphel K, Abolmaali N, Seidlitz A, Appold S, Krause M, Steinbach J, Kotzerke J, Zips D, Baumann M, Troost EGC. FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients. Radiother Oncol 2019;130:97-103. [PMID: 30293643 DOI: 10.1016/j.radonc.2018.09.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
31 Stieb S, Eleftheriou A, Warnock G, Guckenberger M, Riesterer O. Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy. Eur J Nucl Med Mol Imaging 2018;45:2201-17. [PMID: 30128659 DOI: 10.1007/s00259-018-4116-y] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
32 Gainey M, Carles M, Mix M, Meyer PT, Bock M, Grosu AL, Baltas D. Biological imaging for individualized therapy in radiation oncology: part I physical and technical aspects. Future Oncol 2018;14:737-49. [PMID: 29521520 DOI: 10.2217/fon-2017-0464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
33 Verduin M, Compter I, Steijvers D, Postma AA, Eekers DBP, Anten MM, Ackermans L, Ter Laan M, Leijenaar RTH, van de Weijer T, Tjan-Heijnen VCG, Hoeben A, Vooijs M. Noninvasive Glioblastoma Testing: Multimodal Approach to Monitoring and Predicting Treatment Response. Dis Markers 2018;2018:2908609. [PMID: 29581794 DOI: 10.1155/2018/2908609] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
34 Mottaghy FM. Non-invasive molecular imaging and theranostic probes. Methods 2017;130:1-3. [PMID: 28987915 DOI: 10.1016/j.ymeth.2017.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
35 Thorwarth D, Wack L, Mönnich D. Hypoxia PET imaging techniques: data acquisition and analysis. Clin Transl Imaging 2017;5:489-96. [DOI: 10.1007/s40336-017-0250-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
36 Yaromina A, Granzier M, Biemans R, Lieuwes N, van Elmpt W, Shakirin G, Dubois L, Lambin P. A novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the “Low Drug Uptake Volume”. Radiotherapy and Oncology 2017;124:513-20. [DOI: 10.1016/j.radonc.2017.04.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
37 Löck S, Perrin R, Seidlitz A, Bandurska-Luque A, Zschaeck S, Zöphel K, Krause M, Steinbach J, Kotzerke J, Zips D, Troost EGC, Baumann M. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging. Radiother Oncol 2017;124:533-40. [PMID: 28843726 DOI: 10.1016/j.radonc.2017.08.010] [Cited by in Crossref: 86] [Cited by in F6Publishing: 92] [Article Influence: 14.3] [Reference Citation Analysis]
38 Gallez B, Neveu M, Danhier P, Jordan BF. Manipulation of tumor oxygenation and radiosensitivity through modification of cell respiration. A critical review of approaches and imaging biomarkers for therapeutic guidance. Biochimica et Biophysica Acta (BBA) - Bioenergetics 2017;1858:700-11. [DOI: 10.1016/j.bbabio.2017.01.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
39 Vāvere AL, Scott PJH. Clinical Applications of Small-molecule PET Radiotracers: Current Progress and Future Outlook. Semin Nucl Med 2017;47:429-53. [PMID: 28826519 DOI: 10.1053/j.semnuclmed.2017.05.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
40 Peerlings J, Van De Voorde L, Mitea C, Larue R, Yaromina A, Sandeleanu S, Spiegelberg L, Dubois L, Lambin P, Mottaghy FM. Hypoxia and hypoxia response-associated molecular markers in esophageal cancer: A systematic review. Methods. 2017;130:51-62. [PMID: 28705470 DOI: 10.1016/j.ymeth.2017.07.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
41 Lindblom E, Dasu A, Uhrdin J, Even A, van Elmpt W, Lambin P, Wersäll P, Toma-Dasu I. Defining the hypoxic target volume based on positron emission tomography for image guided radiotherapy - the influence of the choice of the reference region and conversion function. Acta Oncol 2017;56:819-25. [PMID: 28464740 DOI: 10.1080/0284186X.2017.1293289] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
42 Welz S, Mönnich D, Pfannenberg C, Nikolaou K, Reimold M, La Fougère C, Reischl G, Mauz PS, Paulsen F, Alber M, Belka C, Zips D, Thorwarth D. Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. Radiother Oncol 2017;124:526-32. [PMID: 28434798 DOI: 10.1016/j.radonc.2017.04.004] [Cited by in Crossref: 93] [Cited by in F6Publishing: 87] [Article Influence: 15.5] [Reference Citation Analysis]
43 Cao J, Liu Y, Zhang L, Du F, Ci Y, Zhang Y, Xiao H, Yao X, Shi S, Zhu L, Kung HF, Qiao J. Synthesis of novel PEG-modified nitroimidazole derivatives via “hot-click” reaction and their biological evaluation as potential PET imaging agent for tumors. J Radioanal Nucl Chem 2017;312:263-76. [DOI: 10.1007/s10967-017-5210-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]